CanaQuest is focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company intends to treat neurological conditions, such as anxiety, depression, schizophrenia, epilepsy, and Post Traumatic Stress Disorder “PTSD”, including addiction.
CanaQuest’s mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies.
CanaQuest’s strategy is to:
- Continue developing scientific-backed proprietary formulations with its scientific partners, backed by pre-clinical trial results.
- Conduct clinical trials for drug candidates with universities and institutions (pre-approved & funded, and pending clinical trials)
- Partner with a global pharmaceutical organization.
CanaQuest has research and clinical trial collaborations with multiple Canadian universities, including a Western University team led by Dr. Steven Laviolette, a neuroscientist, who has decades of research and pre-clinical trial experience, focused on novel cannabinoid and botanical pharmacotherapies, addressing neurological conditions. www.laviolettelab.com
The Company has brought together a wealth of management, commercialization, research & development, clinical trial, and regulatory expertise. As well, advanced manufacturing and pharmaceutical marketing/sales capabilities are in place.
CanaQuest is leveraging its multidisciplinary expertise by strengthening its Board of Directors and inviting Physicians, Psychiatrists, Healthcare Practitioners and regulatory professionals to join its Medical Advisory Board.
Advisor Shared Values and Expertise
- Shared passion to make a real difference in quality of life
- Scientific knowledge and expertise in cannabinoid-based medicine
- Currently or amenable to prescribing cannabinoids.
The Company is following the same regulatory pathway that GW Pharma took to obtain approvals for Epidiolex to treat Dravet & Lennox Gastaut Syndromes, rare neurological conditions under the umbrella of epilepsy.
Regulatory pathways are mapped out for RX CQ-001 to obtain Rx Drug Identification Numbers (DINs) in the USA and Canada for Epilepsy rare neurological conditions, with projected approvals in about 3 years.
Pre-clinical trials have been completed by Western University for Rx CQ-001 & Rx CQ-002.
Drug candidate, Rx CQ-001, supported by (CBD molecules + formula) – molecules bond and synergistically attach to PPAR receptor allowing Rx CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself does not do this.
Epidiolex Formula is 99% CBD – sesame as carrier oil (non-active).
Pre-approved and pending clinical trials are as follows:
University of Montreal
Q2 2022 – initiating pre-approved clinical trial (Phase II, randomized, triple-blind crossover feasibility study) for efficacy and dosage of our cannabinoid based formulated drug-candidates, Rx CQ-001 and Rx CQ-002, for the treatment of Cannabis Use Disorder “CUD”. https://labo-jutras-aswad.ca/en/laboratory/
Q2 2022 – initiating clinical trial (Phase II, double-blind feasibility trial, 30 patients) to further refine efficacy and dosage of Rx CQ-001 for humans.
Ontario Brain Institute
Q1 2022 – EpLink https://eplink.ca/, the Epilepsy Research Program funded by the Ontario Brain Institute, will conduct a study using rodent models to establish dosing requirements for Rx CQ-001. These results will set the stage for clinical trials to treat refractory epileptic syndromes (high efficacy, less dosage, reduced negative side effects).
Q4 2022 – study results will define dosage of Rx CQ-001 for clinical trial (Phase II/III, double-blind trial, 60 patients) and will facilitate a submission to Health Canada and subsequently, the US-FDA for a new drug.
Pre-approved and Pending Clinical Trials
The Company is primed to realize the infinite potential of targeted therapeutics within the endocannabinoid system and specific brain receptors to mediated signaling pathways.